Targeting Host Cell Proteases as a Potential Treatment Strategy to Limit the Spread of SARS-CoV-2 in the Respiratory Tract

December 2020 in “ Pharmacology Research & Perspectives ”

Ismail Amr El-Shimy, Mahmoud Mohamed, Syed Shahzad Hasan, Muhammad Abdul Hadi

TMPRSS2 camostat nafamostat mesilate protease inhibitors remdesivir SARS-CoV-2 COVID-19 viral entry host cell proteases TMPRSS2 inhibitors nafamostat coronavirus virus entry host cell enzymes

Studysummary This review discusses targeting host cell proteases as a novel approach to inhibit SARS-CoV-2 infection, highlighting transcriptional modulation and enzymatic inhibition as promising therapeutic strategies, but it reports no new clinical findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Targeting Host Cell Proteases as a Potential Treatment Strategy to Limit the Spread of SARS-CoV-2 in the Respiratory Tract

15 citations , December 2020 in “Pharmacology Research & Perspectives”

This review discusses targeting host cell proteases as a novel approach to inhibit SARS-CoV-2 infection, highlighting transcriptional modulation and enzymatic inhibition as promising therapeutic strategies, but it reports no new clinical findings.

research Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review

32 citations , July 2016 in “PubMed”

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.